XDx, Inc. entered into a collaboration and license agreement with Laboratory Corporation of America(R) Holdings (LabCorp) to collaborate in discovering biomarkers (potential indicators to monitor disease progress and treatment success). LabCorp will develop and commercialize a diagnostic test to predict flares of systemic lupus erythematosus (SLE). The Lupus Research Institute is actively involved in funding research also looking at developing biomarkers to predict and monitor treatment in lupus. LRI CEO and President Margaret Dowd attended on behalf of all people with lupus a workshop at the U.S. Food and Drug Administration this fall focused on biomarkers as a way to predict worsening of disease, called a flare, and their potential for speeding up lupus clinical trials and new drug approvals.
May 23, 2012